Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset failed to meet the primary endpoints of two phase 2 trials and is scrapping further attempts in the indication as a result.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,